A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion

A Multicenter Randomized Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion

This was a Phase IV multicenter, randomized, open-label study, with masking of the vision examiner, of the efficacy and safety of intravitreal ranibizumab 0.5 mg in subjects with macular edema following Branch Retinal Vein Occlusion (BRVO) or Central Retinal Vein Occlusion (CRVO).

Study Overview

• Status: Completed
• Conditions: Macular Edema
• Intervention / Treatment: Drug: Ranibizumab

Detailed Description

This study consisted of 2 study periods, a 7-month fixed treatment period, followed by an 8-month alternate dose regimen period. Subjects could receive up to a maximum of 15 monthly injections of ranibizumab 0.5 mg during the study, 7 injections (Day 0 and at 6 monthly visits) in the fixed treatment period and a maximum of 8 injections in the alternate dose regimen period. During the fixed treatment period, subjects received 7 monthly intravitreal ranibizumab 0.5 mg injections. During the alternate dose regimen period, from Month 7 through Month 14, subjects were evaluated monthly to determine whether they achieved the study-specific visual acuity and spectral-domain optical coherence tomography (VA-OCT) stability criteria. Subjects continued to receive monthly ranibizumab 0.5 mg monthly injections until the VA-OCT stability criteria were first met. Upon meeting the VA-OCT stability criteria for the first time during the alternate dose regimen period, subjects were randomly assigned in a 1:1 ratio to one of 2 dose regimens, the PRN (pro re nata, "as-needed") or the Monthly regimen.

PRN randomized subjects: Subjects received no injection at the randomization visit and at future monthly visits where the VA-OCT stability criteria were met and received a ranibizumab 0.5 mg injection at future monthly visits if the VA-OCT stability criteria were not met.

Monthly randomized subjects: Subjects continued to receive ranibizumab 0.5 mg injections at each monthly visit.

Monthly non-randomized subjects: Subjects who did not meet the VA-OCT stability criteria at any month from Month 7 through Month 14 were not randomized and received 8 monthly intravitreal ranibizumab 0.5 mg injections.

• Study Type: Interventional
• Enrollment (Actual): 202
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Arizona
    • Phoenix, Arizona, United States, 85020
    • Tucson, Arizona, United States, 85704
  • California
    • Beverly Hills, California, United States, 90211
    • Chico, California, United States, 95973
    • Mountain View, California, United States, 94040
    • Oakland, California, United States, 94609
    • San Francisco, California, United States, 94107
    • Santa Ana, California, United States, 92705
    • Santa Barbara, California, United States, 93103
    • Torrance, California, United States, 90503
  • Colorado
    • Colorado Springs, Colorado, United States, 80909
    • Golden, Colorado, United States, 80401
  • Connecticut
    • New London, Connecticut, United States, 06320
  • Florida
    • Altamonte Springs, Florida, United States, 32701
    • Boynton Beach, Florida, United States, 33426
    • Lakeland, Florida, United States, 33805
  • Georgia
    • Augusta, Georgia, United States, 30909
  • Illinois
    • Chicago, Illinois, United States, 60637
  • Maryland
    • Baltimore, Maryland, United States, 21287
    • Hagerstown, Maryland, United States, 21740
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
    • Worcester, Massachusetts, United States, 01605
  • Michigan
    • Jackson, Michigan, United States, 49201
  • Minnesota
    • Edina, Minnesota, United States, 55435
  • Nevada
    • Las Vegas, Nevada, United States, 89144
  • New Jersey
    • Northfield, New Jersey, United States, 08225
    • Teaneck, New Jersey, United States, 07666
  • New York
    • Rochester, New York, United States, 14620
  • North Carolina
    • Charlotte, North Carolina, United States, 28210
  • Pennsylvania
    • Camp Hill, Pennsylvania, United States, 17011
    • Philadelphia, Pennsylvania, United States, 19107
    • Pittsburgh, Pennsylvania, United States, 15212
    • Pittsburgh, Pennsylvania, United States, 15213
  • South Carolina
    • Ladson, South Carolina, United States, 29456
    • West Columbia, South Carolina, United States, 29169
  • South Dakota
    • Rapid City, South Dakota, United States, 57701
  • Tennessee
    • Nashville, Tennessee, United States, 37203
  • Texas
    • Abilene, Texas, United States, 79606
    • Austin, Texas, United States, 78705
    • Houston, Texas, United States, 77030
    • San Antonio, Texas, United States, 78240
    • The Woodlands, Texas, United States, 77384

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• For sexually active women of childbearing potential, use of an appropriate form of contraception (or abstinence) for the duration of the study.

Ocular Inclusion Criteria (Study Eye)

• Foveal center-involved macular edema secondary to branch retinal vein occlusion (BRVO) (including hemi-retinal retinal vein occlusion [HRVO]) or central retinal vein occlusion (CRVO).
• Best corrected visual acuity (BCVA) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts of 20/40 to 20/320 (Snellen equivalent) in the study eye.
• Mean central subfield thickness > 300 µm on 2 spectral-domain optical coherence tomography measurements (screening and Day 0 [first day of treatment]).

Exclusion Criteria:

• History of cerebral vascular accident or myocardial infarction within 3 months prior to Day 0.
• History of any systemic anti-vascular endothelial growth factor (VEGF) or pro-VEGF treatment within 6 months prior to Day 0.
• History of allergy to fluorescein.
• History of allergy to ranibizumab injection or related molecule.
• Relevant systemic disease that may be associated with increased systemic VEGF levels. History of successfully treated malignancies is not an exclusion criterion.
• Uncontrolled blood pressure.
• Pregnancy or lactation.
• Daily use of oral corticosteroids to treat a chronic condition.
• Required treatment with injectable corticosteroids to treat a musculoskeletal condition.
• Participation in an investigational trial within 30 days prior to Day 0 that involved treatment with any drug or device that has not received regulatory approval at the time of study entry.

Ocular Exclusion Criteria (Study Eye)

• Prior episode of retinal vein occlusion (RVO).
• Brisk afferent pupillary defect.
• History of any previous intravitreal anti-VEGF therapy for RVO in the study eye.
• History of previous therapeutic treatment for RVO, other than anti-VEGF therapy, within 4 months prior to the screening visit, including any intraocular corticosteroids.
• History of previous surgical treatment for RVO, including radial optic neurotomy or sheathotomy.
• History or presence of age-related macular degeneration (AMD) (dry form graded as Age-Related Eye Disease Study [AREDS] Stage 2 or higher or wet form).
• History of laser photocoagulation for macular edema within 4 months prior to Day 0.
• History of panretinal scatter photocoagulation or sector laser photocoagulation within 4 months prior to Day 0 or anticipated within the next 4 months following Day 0.
• History of pars plana vitrectomy.
• History of intraocular surgery within 2 months prior to Day 0 or anticipated within the next 7 months following Day 0.
• History of yttrium-aluminum-garnet (YAG) capsulotomy performed within 2 months prior to Day 0.
• Previous filtration surgery in the study eye.
• History of herpetic ocular infection.
• History of ocular toxoplasmosis.
• History of rhegmatogenous retinal detachment.
• History of idiopathic central serous chorioretinopathy.
• Evidence upon examination of vitreoretinal interface disease either on clinical examination or spectral-domain optical coherence tomography (SD-OCT), thought to be contributing to macular edema.
• Presence of an ocular condition that, in the opinion of the investigator, might affect macular edema or alter visual acuity during the study.
• Visually significant hemorrhage obscuring the fovea and felt to be a major contributor to reduced visual acuity. The subject should be followed and when the hemorrhage in the fovea clears to the point that it is no longer a major contributor to reduced visual acuity, the subject may be screened for the study.
• Presence of a substantial cataract that, in the opinion of the investigator, is likely to be decreasing visual acuity by 3 lines or more.
• Intra-ocular pressure (IOP) ≥ 30 mmHg. If a subject's IOP is ≥ 30 mmHg, that subject will be referred for glaucoma treatment and may be re-screened after 1 month.
• Evidence upon examination of pseudoexfoliation.
• Aphakia.
• Evidence upon examination of external ocular infection, including conjunctivitis, chalazion, or significant blepharitis.
• Evidence upon examination of any diabetic retinopathy, defined as eyes of diabetic patients with more than one microaneurysm outside the area of the vein occlusion (inclusive of both eyes).
• Other relevant ocular disease that may be associated with increased intraocular VEGF levels.
• Improvement of ≥ 10 letters on best-corrected visual acuity ETDRS score between screening and Day 0.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Ranibizumab 0.5 mg monthly - randomized subjects; Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific visual acuity and spectral-domain optical coherence tomography (VA-OCT) stability criteria were met and randomization occurred to the monthly arm. At subsequent monthly visits after randomization, injections were given whether the VA-OCT stability criteria were met or not met. Subjects were to receive 15 ranibizumab 0.5 mg injections.	Drug: Ranibizumab; Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.; Other Names: Lucentis
Experimental: Ranibizumab 0.5 mg PRN - randomized subjects; Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections until the first month where the study-specific VA-OCT stability criteria were met and randomization occurred to the PRN arm. No injection was given at the randomization visit. At subsequent monthly visits after randomization, injections were given if the VA-OCT stability criteria were not met and no injections were given if the VA-OCT stability criteria were met. Subjects could receive between 7 and a maximum of 14 ranibizumab 0.5 mg injections.	Drug: Ranibizumab; Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.; Other Names: Lucentis
Experimental: Ranibizumab 0.5 mg monthly - non-randomized subjects; Subjects received at least 7 monthly intravitreal ranibizumab 0.5 mg injections and then never met the study-specific VA-OCT stability criteria from month 7 to month 14. Subjects were to receive 15 ranibizumab 0.5 mg injections.	Drug: Ranibizumab; Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.; Other Names: Lucentis

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Trend of Change From Baseline in the Best Corrected Visual Acuity (BCVA) Scores From Month 7 to Month 15	BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement. The reported data are the observed changes from Baseline in BCVA at Months 7 and 15. For the statistical analysis, the interaction term of treatment by time in a longitudinal model was used to assess whether there was a difference in the trend of change from Baseline in the visual acuity scores from Month 7 to Month 15 between the 2 randomized treatment groups, Monthly and PRN.	Baseline to Month 15

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Visual Acuity Change From Previous Month During the Alternate Dose Regimen Period in Subjects Who Met the VA-OCT Stability Criteria at the Previous Month	BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement. This outcome measure is not relevant for subjects in the non-randomized group because they never met the VA-OCT stability criteria.	Month 7 through Month 15
Percentage of Participants Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline	BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.	Month 7 to Month 15
Percentage of Participants With a Visual Acuity (VA) Snellen Equivalent of 20/40 or Better	VA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart starting at a test distance of 4 meters. An increase in the number of lines read correctly by the patient in the ETDRS chart indicates an improvement of vision. The Snellen equivalent of 20/40 or better is 69 or more letters correctly read in the EDTRS chart.	Month 7 to Month 15
Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score	BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision. A positive change score indicates improvement.	Month 1 to Month 15
Percentage of Participants Who Lost < 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline	BCVA was measured in the study eye using the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart starting at a test distance of 4 meters. The BCVA score is the number of letters read correctly by the patient. An increase in the BCVA score indicates an improvement of vision.	Month 7 to Month 15
Percentage of Participants With a Central Foveal Thickness of ≤ 300 µm	Central foveal thickness was assessed monthly in the study eye using spectral-domain optical coherence tomography. Central foveal thickness was computed using the automated Cirrus Review software (DOCTR CZM Cirrus OCT Grader Reading Manual, Version 1.02). All participants in the Monthly and PRN groups had a baseline central foveal thickness > 300 µm at baseline.	Month 7 to Month 15
Mean Change From Baseline in Central Foveal Thickness	Central foveal thickness was assessed monthly in the study eye using spectral-domain optical coherence tomography. Central foveal thickness was computed using the automated Cirrus Review software (DOCTR CZM Cirrus OCT Grader Reading Manual, Version 1.02). All participants in the Monthly and PRN groups had a baseline central foveal thickness > 300 µm at baseline. A decrease in foveal thickness suggests a reduction in macular edema. A negative change score indicates improvement.	Month 1 to Month 15
Percentage of Participants With Intraretinal Edema	The presence of intraretinal edema was defined as the presence of subretinal fluid, cystoid spaces, or central retinal thickness ≥ 300 µm as evaluated in spectral-domain optical coherence tomography images by the Digital Angiography Reading Center, the central reading center. At baseline, all participants in the Monthly and PRN groups had presence of edema.	Month 7 to Month 15

Collaborators and Investigators

• Sponsor: Genentech, Inc.
• Investigators: Study Director: Gary Sternberg, M.D., Genentech, Inc.

Publications and helpful links

General Publications

• Lloyd Clark W, Liu M, Kitchens J, Wang PW, Haskova Z. Baseline characteristics associated with early visual acuity gains after ranibizumab treatment for retinal vein occlusion. BMC Ophthalmol. 2019 Jan 8;19(1):11. doi: 10.1186/s12886-018-1012-y.

Study record dates

Study Major Dates

• Study Start: February 1, 2011
• Primary Completion (Actual): October 1, 2012
• Study Completion (Actual): October 1, 2012

Study Registration Dates

• First Submitted: January 13, 2011
• First Submitted That Met QC Criteria: January 13, 2011
• First Posted (Estimate): January 14, 2011

Study Record Updates

• Last Update Posted (Estimate): April 23, 2014
• Last Update Submitted That Met QC Criteria: March 27, 2014
• Last Verified: March 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Eye Diseases; Retinal Degeneration; Retinal Diseases; Embolism and Thrombosis; Venous Thrombosis; Thrombosis; Macular Degeneration; Macular Edema; Retinal Vein Occlusion; Edema; Physiological Effects of Drugs; Antineoplastic Agents; Angiogenesis Inhibitors; Angiogenesis Modulating Agents; Growth Substances; Growth Inhibitors; Ranibizumab
• Other Study ID Numbers: FVF4967g; ML01296 (Other Identifier: Hoffmann-La Roche)